Who are Parsabiv's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): AMG 073, Experimental: SNF472, Sensipar.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/etelcalcetide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Parsabiv — Competitive Intelligence Brief

Parsabiv (ETELCALCETIDE) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium-sensing Receptor Agonist. Area: Hematology.

marketed Calcium-sensing Receptor Agonist CaSR Hematology Recombinant protein Live · refreshed every 30 min

Target snapshot

Parsabiv (ETELCALCETIDE) — Kai Pharms Inc. Etelcalcetide enhances calcium-sensing receptor activation, reducing PTH secretion.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Parsabiv TARGET	ETELCALCETIDE	Kai Pharms Inc	marketed	Calcium-sensing Receptor Agonist	CaSR	2017-01-01
AMG 073	AMG 073	Amgen	marketed	Calcimimetic agent	Calcium-sensing receptor (CaSR)
Experimental: SNF472	Experimental: SNF472	Sanifit Therapeutics S. A.	phase 3	Calcimimetic agent	Calcium-sensing receptor (CaSR)
Sensipar	CINACALCET	Amgen	marketed	Calcium-sensing Receptor Agonist	Extracellular calcium-sensing receptor	2004-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium-sensing Receptor Agonist class)

Amgen · 1 drug in this class
Kai Pharms Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Parsabiv — Competitive Intelligence Brief. https://druglandscape.com/ci/etelcalcetide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab